Fovista, an experimental drug from private U.S. biotech Ophthotech, showed impressive results when added to Roche's Lucentis (ranibizumab) in a large mid-stage clinical trial.In the Phase IIb clinical trial involving 449 patients with wet age-related macular degeneration (AMD), those receiving Fovista and Lucentis gained a mean of 10.6 letters of vision on a standard reading chart at 24 weeks, against 6.5 letters for patients on Lucentis alone, Ophthotech said on Wednesday. To see more details visit, www.medscape.com
